ReviewGland surgery2026
SCOUT MD™ for breast and axillary localisation: a narrative review toward a single radar-based platform.
Review in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- OneMark™ breast localisation: integrating diagnosis and surgical guidance-a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Wire-free localisation technologies have transformed the management of non-palpable breast lesions and pathological axillary lymph nodes. Radar-based localisation using the SAVI SCOUT Methods: A narrative review of literature published between January 2016 and January 2026 was undertaken using PubMed-indexed articles, regulatory documentation, manufacturer technical reports and reference lists from key studies of radar-based localisation systems. Key Content and Findings: SCOUT MD™ incorporates miniaturised 5-mm reflectors with up to four uniquely identifiable radar signatures enabling multi-target localisation. The reflectors can be discriminated individually by their unique signal signatures, without signal overlap. The system supports ultrasound, stereotactic mammography, magnetic resonance imaging (MRI) and computed tomography (CT)-guided deployment. Clinical evidence currently consists primarily of early technical reports and a single case report. Conclusions: SCOUT MD™ addresses recognised technical limitations of single-reflector radar localisation systems, particularly in multi-target localisation and tight bracketing scenarios. However, independent clinical evidence remains limited and prospective clinical studies are required to establish its comparative effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.